Sugi Predict

Sugi Predict / Compounds / SCHEMBL29673308

SCHEMBL29673308

SCHEMBL29673308

CC(C)(C)OC(=O)NCc1cc2nc(Cl)ccc2cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4A O75164 1/20 0.42
▸ STK17B O94768 1/20 0.41
▸ STK17A Q9UEE5 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ ACACA Q13085 1/20 0.41
▸ MAPKAPK2 P49137 2/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ PDPK1 O15530 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ ATR Q13535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29673310 1.00 KDM4A (0.42) KDM4ASTK17BSTK17AACACBACACA
SCHEMBL23705506 1.00 KDM4A (0.42) KDM4ASTK17BSTK17AACACBACACA
SCHEMBL31396209 0.85 AAK1 (0.47) KDM4ASTK17BSTK17AMAPKAPK2DYRK1A
SCHEMBL31401432 0.83 GAA (0.42) KDM4ASTK17BSTK17AMAPKAPK2DYRK1A
SCHEMBL23706123 0.83 ACACB (0.47) KDM4AACACBACACADYRK1A
SCHEMBL23705919 0.82 L3MBTL1 (0.36) L3MBTL1POLBMAPK1ATM
SCHEMBL30096989 0.81 KDM4A (0.43) KDM4AACACBACACADYRK1APDPK1
SCHEMBL30042246 0.81 KDM4A (0.43) KDM4AACACBACACADYRK1APDPK1
SCHEMBL26141725 0.81 KDM4A (0.43) KDM4AACACBACACADYRK1APDPK1
SCHEMBL23706015 0.80 L3MBTL1 (0.41) KDM4AACACBACACAL3MBTL1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739686-A1 SMARCA2 INHIBITOR USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
EP-4739684-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 — — EP disclosed
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 — — US disclosed
EP-4522280-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
US-20250066354-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-02-27 — — US disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
WO-2025008060-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
WO-2025008436-A1 SMARCA2 INHIBITOR USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 — — WO disclosed
US-12139487-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2024-11-12 — — US disclosed
US-20230416248-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-12-28 — — US disclosed
US-20230365560-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-16 — — US disclosed
WO-2023220219-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
EP-4244213-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2023-09-20 — — EP disclosed
CN-116745288-A Compounds and uses thereof 福霍恩治疗公司 2023-09-12 — — CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 — — US disclosed
EP-4096668-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
CN-115297861-A Compound and use thereof 福宏治疗公司 2022-11-04 — — CN disclosed
WO-2022103899-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066354-A1 COMPOUNDS AND USES THEREOF BRCA1, VHL, TFEB KDM4A 2278/4885STK17B 3560/4885STK17A 3545/4885
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB KDM4A 2166/4885STK17B 3158/4885STK17A 3608/4885
US-20230416248-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KDM4A 2166/4885STK17B 3158/4885STK17A 3608/4885
US-12139487-B2 Compounds and uses thereof BRCA1, VHL, TFEB KDM4A 2278/4885STK17B 3560/4885STK17A 3545/4885
US-20230365560-A1 COMPOUNDS AND USES THEREOF BRCA1, VHL, TFEB KDM4A 2278/4885STK17B 3560/4885STK17A 3545/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB KDM4A 2166/4885STK17B 3158/4885STK17A 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.